Etoposide and Cisplatin Chemotherapy for Metastatic Good-Risk Germ Cell Tumors
| Autor: | George J. Bosl, Jennifer Bacik, Robert J. Motzer, Dean F. Bajorin, Joel Sheinfeld, Deborah Dobrzynski, G. Varuni Kondagunta |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Bleomycin Risk Assessment Disease-Free Survival chemistry.chemical_compound Testicular Neoplasms Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Retroperitoneal Neoplasms Etoposide Cisplatin Chemotherapy business.industry Neoplasms Germ Cell and Embryonal Prognosis medicine.disease Surgery Regimen chemistry Teratoma Metastatic Germ Cell Tumor Germ cell tumors business medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 23:9290-9294 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2005.03.6616 |
| Popis: | Purpose To assess response, overall survival, and relapse-free survival of patients with good-risk metastatic germ cell tumor (GCT) by International Germ Cell Consensus Classification Group (IGCCCG) criteria treated with four cycles of etoposide and cisplatin (EP). Patients and Methods Two hundred eighty-nine patients with IGCCCG good-risk GCT were treated with four cycles of EP. EP consisted of four cycles of etoposide 100 mg/m2 and cisplatin 20 mg/m2 on days 1 to 5 every 21 days. Results Two hundred eighty-two of 289 patients (98%) achieved a complete response; 269 (93%) responded to chemotherapy alone and 13 (5%) responded to chemotherapy plus surgical resection of viable disease (GCT other than mature teratoma). Seventeen (6%) experienced relapse, and nine (3%) died as a result of disease at a median follow-up of 7.7 years (range, 0.4 to 21.1 years). Sixty-two of 204 patients (30%) with nonseminoma had findings of teratoma or viable GCT at postchemotherapy surgery. Conclusion Four cycles of EP is a highly effective therapy for patients with good-risk GCT, with a high cure rate, low relapse rate, and little evidence of late relapse. Postchemotherapy surgery resection of residual disease remains an important aspect of treatment for these patients. Four cycles of EP is acceptable as a standard regimen for the treatment of good-risk metastatic GCT, and serves as an alternative to three cycles of bleomycin and etoposide before cisplatin. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|